SynthesisInflammatory bowel diseases2023

Systematic Review and Meta-analysis: Loss of Response and Need for Dose Escalation of Infliximab and Adalimumab in Ulcerative Colitis.

Edo H J Savelkoul et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.